Assembly Biosciences Inc (ASMB) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Assembly Biosciences Inc stock $8.51, price $20.42, that is 58.3% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range $7.77 – $46.80 · fair‑value band $5.61 – $10.63 · the $20.42 price screens above the $8.51 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Assembly Biosciences in your weekly email
Every Wednesday you see whether Assembly Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Show moreShow less
Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses.
It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Stock analysis
Assembly Biosciences Inc (ASMB) currently trades at $20.42, while our model-based Fair Value estimate is $8.51, 58% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $5.61 (bear) to $10.63 (bull), the price of $20.42 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Assembly Biosciences Inc reported revenue of $72.3M in FY2025 versus $6.3M in FY2021, a compound +84.4%/yr. Reported net income was −$6.1M in FY2025.
Key figures
Market cap $385M Small · P/S ratio 5.35 · EPS (TTM) $1.04 · Net margin −8.5% · Return on equity 0.0% · Return on assets (EBIT) −50.4% (5-year average) · Operating margin −47.4% · Revenue (TTM) $74.8M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −58%, ASMB screens richer than that median.
Fair Value models
Bear$5.61Fair Value $8.51Bull$10.63
Price $20.42 · Downside -58.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.8918 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$6.60$10.01$12.5154
All 1 models by family
Asset-Based
NCAV (Graham)$6.60$10.01$12.5154
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, 4 officers or directors sold shares worth $238,322 and none bought.
SaleJason A OkazakiCEO and President, Director6,202 shares at $19.62$121,658Nov 2, 2026
SaleAnuj GaggarChief Medical Officer2,593 shares at $19.62$50,864Nov 2, 2026
SaleNicole S WhiteChief Manufacturing Officer2× since Mar 30, 2026: 2,790 shares, avg. $20.12$56,122Nov 2, 2026
SaleJeanette M BjorkquistPFO and PAO3× since Mar 30, 2026: 1,084 shares, avg. $21.85$23,690Nov 2, 2026
Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+153.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.8%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.7%
’17
’18
’19
’20
’21
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−81.9% (2020) → −16.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Assembly Biosciences Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score41 · Below median
Fair Value upside−58.3% · Below median
Profitability
Return on assets−2.4% · Above median
Net margin (12 months)−0.1% · Below median
Operating margin (12 months)−47.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)38.9% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.86× · Cheaper than median
P/S (12 months)5.14× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Assembly Biosciences Inc (ASMB) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $8.51 versus a price of $20.42, about 58% lower (overvalued).
What is the fair value of ASMB?
Our model-based fair value for Assembly Biosciences Inc is $8.51 (as of Nov 8, 2026), built from audited fundamentals. The current price: $20.42.
What is the quality score of ASMB?
Assembly Biosciences Inc has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Assembly Biosciences Inc (ASMB)?
Our model-based price target is the fair value of $8.51 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $5.61, optimistic scenario $10.63. It is a calculation from audited fundamentals, not an analyst target.
What is the Assembly Biosciences Inc stock forecast for 2026?
Our models put fair value at $8.51, about 58% lower versus a price of $20.42 (overvalued). Cautious scenario $5.61, optimistic scenario $10.63. The calculation is refreshed regularly with new filings.
What is the revenue of Assembly Biosciences Inc (ASMB)?
Assembly Biosciences Inc reported trailing-twelve-month revenue of about $74.8M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Assembly Biosciences Inc (ASMB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Assembly Biosciences Inc it is $8.51 per share (as of Nov 8, 2026), against a price of $20.42. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Assembly Biosciences Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, ASMB trades above its calculated fair value: price $20.42, fair value $8.51, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ASMB?
No. The price is what the market pays today ($20.42); the fair value is what the company's own numbers justify ($8.51). For Assembly Biosciences Inc the two are $11.91 per share apart. That gap is exactly why we show both numbers side by side.
How much is Assembly Biosciences Inc worth?
The market values Assembly Biosciences Inc at about $385M (market capitalisation, as of Nov 8, 2026). Per share that is $20.42; our models calculate a fair value of $8.51 per share.
What do the bullish and bearish scenarios say about ASMB?
Our models span a range for Assembly Biosciences Inc: cautious scenario $5.61, base $8.51, optimistic $10.63 per share (as of Nov 8, 2026, price $20.42). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Assembly Biosciences Inc (ASMB)?
Balance-sheet figures for Assembly Biosciences Inc (as of Nov 8, 2026): return on equity 0.0%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is ASMB from its 52-week high?
Assembly Biosciences Inc trades at $20.42, about 47% below its 52-week high of $38.50 and 5% above the low of $19.51 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $8.51 is for.
Which stocks are comparable to Assembly Biosciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Assembly Biosciences Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $20.42, calculated fair value $8.51 (−58%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ASMB calculated?
We run Assembly Biosciences Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $8.51 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Assembly Biosciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Assembly Biosciences Inc (ASMB)?
The closing price on Nov 6, 2026 was $20.42. Our model-based fair value is $8.51, about 58% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Assembly Biosciences Inc right now?
The price sits above even our optimistic bull case ($10.63). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($5.61 to $10.63) leaves room in how you read the outcome.
Key figures of Assembly Biosciences Inc
How large is the market capitalisation of Assembly Biosciences Inc (ASMB)?
The market capitalisation of Assembly Biosciences Inc is $385M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Assembly Biosciences Inc (ASMB)?
The price-to-sales ratio of Assembly Biosciences Inc is 5.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Assembly Biosciences Inc (ASMB)?
Earnings per share at Assembly Biosciences Inc are $1.04. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Assembly Biosciences Inc (ASMB)?
The net margin of Assembly Biosciences Inc is −8.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Assembly Biosciences Inc (ASMB)?
The return on equity (ROE) of Assembly Biosciences Inc is 0.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Assembly Biosciences Inc (ASMB)?
On an EBIT basis the return on assets of Assembly Biosciences Inc is −50.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Assembly Biosciences Inc (ASMB)?
The operating margin of Assembly Biosciences Inc is −47.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Assembly Biosciences Inc (ASMB)?
Revenue at Assembly Biosciences Inc is growing +38.9% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Assembly Biosciences Inc (ASMB) generate?
The free cash flow of Assembly Biosciences Inc is −$41.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Assembly Biosciences Inc (ASMB) hold?
Assembly Biosciences Inc holds more cash than debt, $55.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Assembly Biosciences Inc in the live analysis
One click puts Assembly Biosciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
